Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, ...

Results from Lundbeck's open-label portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in treatment ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Beigene has chosen to scrap ociperlimab after analysis found the lung cancer drug wouldn't its endpoint in extending overall survival.

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...